EMPAGLIFLOZIN; LINAGLIPTIN | N206073 | BOEHRINGER INGELHEIM
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2016-01563 | 8673927 | IPR | Mylan Pharmaceuticals Inc. et al. | Terminated | 2016-08-10 | — |
| IPR2016-01566 | 9173859 | IPR | Mylan Pharmaceuticals Inc. et al. | Institution Denied | 2016-08-10 | — |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Annora Pharma Private Limited et al 1 patentANDA 212364empagliflozin/linagliptin | D. Del. | 2020-02-25 | Terminated 2020-11-10 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 7579449 | Aug 1, 2028PED: Feb 1, 2029 | PED | Yes | — | — | — |
| 7713938 | Apr 15, 2027PED: Oct 15, 2027 | PED | Yes | Yes | — | — |
| 8551957 | Oct 14, 2029PED: Apr 14, 2030 | PED | — | Yes | — | |
| 8673927 | May 4, 2027PED: Nov 4, 2027 | PED | — | — | Delisted | |
| 8883805 | Nov 26, 2025PED: May 26, 2026 | PED | — | Yes | — | — |
| 9173859 | May 4, 2027 | — | — | Yes | Delisted | |
| 9949998 | Jun 11, 2034 | — | — | — | — | |
| 10258637 | Apr 3, 2034PED: Oct 3, 2034 | PED | — | — | — | |
| 11033552 | May 4, 2027PED: Nov 4, 2027 | PED | — | Yes | — | — |
| 11090323 | Apr 3, 2034PED: Oct 3, 2034 | PED | — | — | — | |
| 11833166 | Apr 3, 2034PED: Oct 3, 2034 | PED | — | — | — | |
| 12115179 | Feb 11, 2030PED: Aug 11, 2030 | PED | — | — | — | |
| 12178819 | May 4, 2027 | — | — | Yes | — | — |
| 12364700 | Jun 8, 2037PED: Dec 8, 2037 | PED | — | — | — | |
| 12433906 | Apr 3, 2034PED: Oct 3, 2034 | PED | — | — | — |